12.2

Member state mechanisms on substandard and falsified medical products

This statement is from MMI, supported by PHM and TWN.

We would like to call the attention of MS and the Secretariat to the following issues.

First, even after the finalization of definitions WHO continues to conflate substandard and falsified medicines. Instead of giving separate data on the circulation of substandard and falsified medicine, the Secretariat provides aggregate data of substandard and falsified. This approach is not only erroneous but also helps the scaremongering on quality of medicines.

Secondly, in 2014 MSM called on the Secretariat to provide a Study to deepen understanding of the link between access to quality, safe, efficacious and affordable medical products and the emergence of substandard and falsified medical products. However, there is no progress in concluding the study. We would like to stress that access to medicines can eliminate the incentive for the circulation of falsified medicines.

Third, there should not be any interception of movement of medicines in transit without the request from the regulatory authorities of either export or importing country. The interception in the name of checking movement of substandard or falsified will result in the interception of generic medicines and compromises access. We call upon the MS to wind up the work on this issue.

Total: 205 words